Delivery Order SPE2DB24D1034-SPE2DB25FWFS8
- Not listed
- The Defense Logistics Agency (DLA) awarded a $1,896.96 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. This firm fixed-price delivery order was competitively awarded with no set-aside designation and carries an ultimate completion date of July 23, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate...
- The Defense Logistics Agency awarded a $3,274.31 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60 ml), a pharmaceutical product used in treating attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,154.08 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension (60 mL), a pharmaceutical product used in the treatment of attention-deficit/hyperactivity disorder. This firm fixed-price delivery order, issued on August 5, 2025, represents a non-set-aside competitive award with an ultimate completion date of August 6, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $2,230.34 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (60 ml), a pharmaceutical product used to treat attention-deficit/hyperactivity disorder. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order with an ultimate completion date of September 9, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor...
- The Defense Logistics Agency awarded a delivery order valued at $2,467.42 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. This firm fixed-price delivery order, issued on September 8, 2025, with completion expected by September 9, 2025, represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $1,464.90 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL), a medication commonly used to treat attention deficit hyperactivity disorder. This firm fixed-price delivery order, awarded on August 6, 2025, is non-competitive and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through...
- The Defense Logistics Agency (DLA) awarded a $1,182.78 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (150 ml), with an ultimate completion date of June 20, 2025. This non-set-aside award was issued on June 18, 2025, with performance to be executed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, was selected...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,814.83 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (180 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. The contract is a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The award was executed on June 2, 2025, with an ultimate completion date of June 3, 2025, and performance...
- The Defense Logistics Agency awarded a delivery order valued at $1,609.51 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml Suspension (180 ml), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. This competitively awarded, firm fixed-price delivery order was issued on August 14, 2025, with an ultimate completion date of August 15, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The...
- The Defense Logistics Agency awarded a delivery order valued at $1,764.78 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml), a medication commonly used to treat attention deficit hyperactivity disorder. This firm fixed-price delivery order, awarded on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a non-competitive set-aside award. The product will be delivered to AmerisourceBergen's corporate office location in...
- SPE2DB24D1034Indefinite Delivery Contract
- SPE2DB24D1034-SPE2DB25FWFS8Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,488.90 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (60 mL), a pharmaceutical product used in the treatment of attention deficit hyperactivity disorder. This firm fixed-price delivery order was competitively awarded without set-aside provisions and is scheduled for completion by September 12, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery from its corporate office location in Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million and extending through December 2026. The IDC serves as a comprehensive vehicle for supplying a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp's federal contract portfolio demonstrates extensive experience fulfilling DLA medical procurement requirements across multiple therapeutic domains, including specialty medications, vaccines, and medical supplies, positioning the company as a critical vendor for Department of Defense healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 9/11/25 |